Gynecologic Oncology

Cytology dual-stain biomarker for detecting HPV-driven cervical precancer

December 27, 2021

A prospective observational screening study has concluded a cytology dual-stain (DS) biomarker effectively triages women who test positive for primary human papillomavirus (HPV) and are at higher risk of developing cervical cancer, irrespective of the HPV genotype.

Impact of HPV vaccine on cervical cancer

December 21, 2021

Human papillomavirus (HPV) vaccination has significantly decreased the incidence and mortality of cervical cancer in girls and women between the ages of 15 and 24, according to a research letter in JAMA Pediatrics.

Novel drug has potential to ‘become new standard of care’ in advanced, ER-positive breast cancer

December 10, 2021

The study results — which were presented during the 2021 San Antonio Breast Cancer Symposium — indicated that elacestrant, a selective estrogen receptor degrader (SERD), led to a 30% reduction in the risk of disease progression or death compared with standard of care in the study population.

Niraparib Demonstrates PFS Benefit in Chinese Population With Advanced Ovarian Cancer

December 01, 2021

First-line maintenance treatment with the PARP inhibitor niraparib yielded a clinically meaningful and statistically significant improvement in progression-free survival vs placebo in Chinese patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status, according to data from the phase 3 PRIME trial.